Aortic stenosis
A Cleveland Clinic Journal of Medicine primer distills what clinicians need to know about Lp(a) risk, screening and emerging therapies (Cleve Clin J Med 2025)
Original title: Lipoprotein(a) in clinical practice: What clinicians need to know
This practice-oriented review by Al-Dalakta, Cho and Sarraju summarises elevated lipoprotein(a) as an independent risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis, aimed at practicing clinicians. It covers current screening strategies, notes that available lipid-lowering treatments have minimal effect on Lp(a), and surveys emerging Lp(a)-targeted therapies now in phase 3 cardiovascular outcomes trials. A concise clinical primer rather than new research, intended to translate the growing Lp(a) evidence base into practical guidance for risk assessment and patient counselling ahead of anticipated therapy approvals.
Original abstract
Elevated lipoprotein(a) is an independent risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis. Current lipid-lowering treatments have a minimal impact on lipoprotein(a) levels, but emerging therapies show promise, and ongoing phase 3 trials are evaluating their effect on cardiovascular outcomes. This review summarizes evidence on risk, screening strategies, and evolving therapies for elevated lipoprotein(a).
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.